{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-022947","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2025-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.652191+00:00","generated_at":"2026-05-24T22:14:39.463961+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"OptimizeRx Q4 revenue up 14% to $32.3M; FY2025 guidance at least $100M revenue","bullets":["Q4 revenue $32.3M (+14% YoY); gross profit $22.0M (+23% YoY, margin 68%).","GAAP net loss $(0.1)M in Q4; full-year GAAP net loss $(20.1)M or $(1.10)/share.","Non-GAAP net income $5.5M ($0.30 diluted) in Q4; Adj. EBITDA $8.8M (+53% YoY).","FY2025 guidance: revenue at least $100M, adjusted EBITDA at least $12M.","Net revenue retention 121% in 2024 vs 105% in 2023; 48 DAAP deals (up from 24)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-022947","json":"https://secwatch.observer/filing/0001213900-25-022947.json","markdown":"https://secwatch.observer/filing/0001213900-25-022947.md","text":"https://secwatch.observer/filing/0001213900-25-022947.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000121390025022947/0001213900-25-022947-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000121390025022947/ea0234059-8k_optimize.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T22:14:39.463961+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}